NPC
ALXN

National Planning Corporation’s Alexion Pharmaceuticals ALXN Stock Holding History

National Planning Corporation’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,853
Closed -$260K – 676
2017
Q3 		$260K Buy
+1,853
New +$252K 0.02% 558
2016
Q4 		– Sell
-3,263
Closed -$392K – 736
2016
Q3 		$392K Sell
3,263
-13
-0.4% -$1.67K 0.03% 413
2016
Q2 		$438K Hold
3,276
– – 0.03% 409
2016
Q1 		$462K Sell
3,276
-2,220
-40% -$326K 0.04% 370
2015
Q4 		$782K Buy
5,496
+113
+2% +$19.7K 0.06% 298
2015
Q3 		$945K Sell
5,383
-1,437
-21% -$262K 0.09% 220
2015
Q2 		$1.27M Buy
+6,820
New +$1.18M 0.11% 183
2015
Q1 		– Sell
-324
Closed -$60.9K – 2247
2014
Q4 		$60.9K Sell
324
-1,648
-84% -$305K ﹤0.01% 1164
2014
Q3 		$351K Sell
1,972
-500
-20% -$82.1K 0.03% 510
2014
Q2 		$386K Sell
2,472
-100
-4% -$15.8K 0.03% 496
2014
Q1 		$397K Sell
2,572
-200
-7% -$31.8K 0.03% 448
2013
Q4 		$367K Sell
2,772
-57
-2% -$6.84K 0.03% 466
2013
Q3 		$334K Buy
2,829
+22
+0.8% +$2.41K 0.03% 460
2013
Q2 		$258K Buy
+2,807
New +$271K 0.03% 423

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

National Planning Corporation's ALXN Position: Q4 2017 in Review

National Planning Corporation sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 1,853 shares — an estimated $260K sold.

National Planning Corporation first reported a position in ALXN in Q2 2013 and held it in 14 quarters. The position peaked at $1.27M in Q2 2015. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • National Planning Corporation reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • National Planning Corporation sold 1,853 Alexion Pharmaceuticals shares in Q4 2017, an estimated $260K.
  • National Planning Corporation first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • National Planning Corporation's Alexion Pharmaceuticals position peaked at $1.27M in Q2 2015.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on National Planning Corporation's 13F filing for Q4 2017, filed 14 Feb 2018.